The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands.
6
Citation
0
Reference
10
Related Paper
Citation Trend
Keywords:
Mesalazine
Cite
Objective To explore the clinical effect of Mesalazine combined with probiotics in treating ulcerative colitis.Methods Fifty-five patients with ulcerative colitis were evenly randomly divided into two groups:treatment group and control group.Patients in treatment group were treated with Mesalazine and probiotics,and those in control group only received Mesalazine.The clinical curative effect of two groups was compared.Results The total efficiency rate in treatment group was 92.00%,and it was significantly higher 72.00% in the control group(P 0.05);the relapse rate in the treatment group was 12.00%,and significantly lower than that of 32.00% in the control group(P 0.05).Conclution The combined therapy with Mesalazine and probiotics for ulcerative colitis could significantly raise the clinical efficacy and reduce relapse rate.
Mesalazine
Clinical efficacy
Cite
Citations (2)
Objective: To evaluate the curative effect of Medilac-s capsule combined with mesalazine and the influence on inflammatory factors in patients with ulcerative colitis. Methods: Two hundred and twenty six cases with active ulcerative colitis were randomly divided into the observation group( n = 114) and the control group( n = 112). The observation group were treated with Medilac-s capsule combined with mesalazine while the control group were only treated with mesalazine. The curative effects in the two groups were compared. And the changes of IL-8,TNF-α,MIF and IL-10 in serum from patients with ulcerative colitis in the two groups were also compared.Results: The total efficiency in the observation group was higher than the control group and the difference was statistically significant( P 0. 05). The concentrations of IL-8,TNF-α,MIF and IL-10 in the two groups were not significantly different before treatment( P 0. 05). The concentrations of IL-8 and TNF-α were more lower in the observation group than the control group( P 0. 05),while IL-10 was reverse after treatment( P 0. 05). MIF was lower in the observation group than control group,but there was no statistics significance( P 0. 05). The adverse reactions in the two group were similar( P 0. 05). Conclusion: Medilac-s capsule combined with mesalazine could improve the effective rate in patients with active ulcerative colitis. The two drugs had synergistic effect and could control pathogenetic condition of patients with active ulcerative colitis. The two drugs have biggish clinical application values and good application prospect.
Mesalazine
Capsule
Cite
Citations (1)
Objective To investigate clinical efficacy of mesalazine combined with probiotics in treatment of ulcerative colitis. Methods 64 patients with ulcerative colitis in our hospital were selected as study group and divided into the control group( 32),treated by mesalazine and the study group( 32),treated by mesalazine combined with probiotics. The clinical efficacy and relapse of two groups were observed.Results The total effective rate of the study group( 93. 75%) was significantly higher than that of the control group( 71. 88%)( P 0. 05). Serum C- protein levels of the study group was significantly lower than that of the control group( P 0. 01). The recurrence rate of the study group( 12. 50%) was significantly lower than that of the control group( 34. 38%)( P 0. 05). Conclusion Compared simply using the mesalazine,mesalazine combined with probiotics in treatment of ulcerative colitis has curative effect,low recurrence rate after treatment
Mesalazine
Clinical efficacy
Cite
Citations (1)
Objective: To evaluate the efficacy of probiotics as maintenance treatment in ulcerative colitis.Methods: A total of 58 ulcerative colitis patients with remission were randomized to receive probiotics plus mesalazine(29 patients) and mesalazine(29 patients).Disease activity index and endoscopic and histological scores were calculated in both groups in 0,6,and 12 months and relapse was recorded.Results: No significant difference in relapse rate in 6(P=0.666) and 12 months(P=0.345) was noted between the 2 groups and the same result was found in disease activity index and endoscopic and histological scores in 0,6,and 12 months(P0.05).Conclusions: Mesalazin plus probiotics as maintenance treatment in ulcerative colitis has the same effect as mesalazine alone on maintaining remission of ulcerative colitis in the 1st year.It is unnecessary to use probiotics and mesalazine together as maintenance treatment in ulcerative colitis.
Mesalazine
Maintenance therapy
Cite
Citations (0)
In an open clinical trial 71 patients with ulcerative colitis and 27 patients with Crohn's disease were treated with mesalazine (5-ASA). After four to eight weeks of acute phase treatment, maintenance therapy was ensued by treatment over a period of maximal 48 weeks. The activity of both inflammatory bowel disease clearly decreased. Relapse was not observed during maintenance treatment in ulcerative colitis. Pathological changes of clinical findings were not observed during treatment. Pathologic changes before treatment, which were associated with the disease, returned to normal during treatment. All potential side effects during treatment were recorded. The rate of side effects was low and all normalized when therapy was continued. The study confirms that mesalazine was safe, efficient and almost well tolerable.
Mesalazine
Aminosalicylic acid
Cite
Citations (3)
Aim: To compare the efficacy and tolerability of olsalazine sodium with enteric‐coated mesalazine in inducing endoscopic remission in patients with mild to moderate active ulcerative colitis. Patients and methods: Patients with mild to moderate active ulcerative colitis were randomized to receive either olsalazine sodium, 3 g/day ( n = 88), or mesalazine, 3 g/day ( n = 80), for up to 12 weeks. Results: Of the patients treated with olsalazine sodium, 52.2% achieved endoscopic remission, compared with 48.8% of patients treated with mesalazine. This difference was not significant ( P = 0.67). There was a non‐significant trend for patients with left‐sided colitis or a more severe endoscopic grade to achieve remission if they were treated with olsalazine sodium than if they were treated with mesalazine. Both treatments were comparable with respect to clinical activity index and an investigator’s global assessment. Seventy patients reported one or more adverse events; adverse events were seen in 45% of olsalazine sodium‐treated patients and in 36% of mesalazine‐treated patients. Eleven patients treated with olsalazine sodium and nine patients treated with mesalazine withdrew from the study because of adverse events. One patient treated with olsalazine sodium compared with two treated with mesalazine stopped treatment because of diarrhoea. Serious adverse events occurred in three patients treated with olsalazine sodium and in four treated with mesalazine. Conclusion: Therapeutic effectiveness and tolerance to the treatment did not differ between olsalazine sodium, 3 g/day, and mesalazine, 3 g/day, in inducing endoscopic remission in patients with mild to moderate active ulcerative colitis within 12 weeks of treatment.
Mesalazine
Tolerability
Cite
Citations (58)
Mesalazine
Tolerability
Maintenance therapy
Group B
Cite
Citations (28)
Summary Background Aminosalicylates are the mainstay of therapy to prevent relapse of quiescent ulcerative colitis. The rationale for using probiotics is based on the evidence implicating intestinal bacteria in the pathogenesis of this disorder. Aim To evaluate the efficacy of Lactobacillus GG alone or in combination with mesalazine vs. mesalazine as maintenance treatment in ulcerative colitis. Patients and methods 187 ulcerative colitis patients with quiescent disease were randomized to receive Lactobacillus GG 18 × 10 9 viable bacteria/day (65 patients), mesalazine 2400 mg/day (60 patients) or Lactobacillus GG + mesalazine (62 patients). Disease activity index, endoscopic and histological scores were determined at 0, 6 and 12 months and in case of relapse. The primary end point was to evaluate sustained remission. Results Overall analysis showed no difference in relapse rate at 6 ( P = 0.44) and 12 months ( P = 0.77) among the three treatment groups. However, the treatment with Lactobacillus GG seems to be more effective than standard treatment with mesalazine in prolonging the relapse‐free time ( P < 0.05). Conclusions Lactobacillus GG seems to be effective and safe for maintaining remission in patients with ulcerative colitis, and it could represent a good therapeutic option for preventing relapse in this group of patients.
Mesalazine
Cite
Citations (453)
Objective: To explore the effects of Shenlingbaishu powder combined with salad oxazine on the treatment of ulcerative colitis and its influence on levels of cytokines. Methods: The patients with ulcerative colitis who were treated in our hospital from January 2013 to 2014 were selected and randomly divided into the observation group and the control group. The patients in the observation group were treated by shenlingbaizhu powder combined with mesalazine, while the patients in the control group were treated with the salad oxazine. Then the levels of cytokines in serum of patients were detected and compared between the two groups. Results:The total effective rate of observation group was better than that of the control group with statistically significant difference(P0.05);After the treatment, the Sutherland DAI score of patients in the two groups improved, and the observation group was better than that of the control group with statistically significant difference(P0.01); The expression levels of IL-17, IL-23 and TNF-a reducedand the observation group was lower than those of the control group with statistically significant differences(P0.01). Conclusion: The effect of Shenlingbaizhu powder combined with mesalazine on the treatment of ulcerative colitis could be better with the improvement of the cytokines levels.
Mesalazine
Proinflammatory cytokine
Cite
Citations (0)
Mesalazine
Transplant surgery
Placebo-controlled study
Cite
Citations (117)